stockrowSummit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) EV/Sales
As of 5 November 2026, Summit Therapeutics PLC (SMMT) trades at a EV/Sales of 15,046×. Over the past ten years it has ranged from −31.9× (February 2020) to 38,051× (April 2025); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 1,153× | 637.85% |
| FY2021 | 156× | (48.41%) |
| FY2020 | 303× | — |
| FY2019 | −19.1× | — |
| FY2019 | −0.1× | — |
| FY2018 | 0.1× | (99.77%) |
| FY2018 | 26.0× | (24.10%) |
| FY2017 | 34.3× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | 1,153× | 625.22% |
| Sep 2022 | 159× | 200.69% |
| Jun 2022 | 52.9× | (62.86%) |
| Mar 2022 | 142× | (8.89%) |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PCVX Vaxcyte, Inc. compare | n/m |
| JAZZ Jazz Pharmaceuticals PLC compare | 3.7× |
| BMRN BioMarin Pharmaceutical Inc. compare | 3.9× |
| HALO Halozyme Therapeutics, Inc. compare | 9.0× |
| TECH Bio-Techne Corp compare | 9.3× |
| ASND Ascendis Pharma A/S compare | 13.1× |
| BBIO BridgeBio Pharma, Inc. compare | 15.9× |
| KYMR Kymera Therapeutics, Inc. compare | 111× |
| SMMT Summit Therapeutics PLC | 15,046× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on SMMT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement